Anti–β2-glycoprotein I, antiprothrombin antibodies, and thrombosis: main characteristics of 32 articles on 5102 patients and 1973 controls
. | . | . | . | Isotypes . | . | |
|---|---|---|---|---|---|---|
| Article and reference no. . | No. of patients . | Enrollment criteria . | No. of controls . | Anti—β2-glycoprotein I . | Antiprothrombin . | |
| Cross-sectional | ||||||
| Pasquier et al26 | 241 | Deep vein thrombosis | 157 | G/A/M | G/A/M | |
| Case-control | ||||||
| Vaarala et al27 * | 106 | Myocardial infarction | 106 | G | G | |
| Palosuo et al28 * | 265 | Deep vein thrombosis | 265 | G | G | |
| Previtali et al29 | 79 | Arterial and venous thrombosis | 85 | G/M | G/M | |
| Brey et al30 * | 374/259 | Myocardial infarction/cerebral stroke | 1360 | G | — | |
| Retrospective | ||||||
| Viard et al31 | 47 | Systemic lupus erythematosus | — | G | — | |
| Balestrieri et al32 | 121 | Antiphospholipid syndrome | — | G/M | — | |
| Cabiedes et al33 | 94 | Systemic lupus erythematosus | — | G | — | |
| Cabral et al34 | 15 | Antiphospholipid syndrome | — | G/M | — | |
| Martinuzzo et al35 | 169 | Antiphospholipid antibodies | — | G | — | |
| Amengual et al36 | 120 | Antiphospholipid syndrome | — | G | — | |
| Roubey et al37 | 157 | Systemic lupus erythematosus | — | G | — | |
| Tsutsumi et al38 | 308 | Systemic lupus erythematosus | — | G/M | — | |
| Sanmarco et al39 | 61 | Autoimmune diseases | — | G | — | |
| Day et al40 * | 281 | Antiphospholipid syndrome | — | G/M | — | |
| Fanopoulos et al41 | 48 | Systemic lupus erythematosus | — | G/A/M | — | |
| Zanon et al42 | 227 | Deep vein thrombosis | — | G/M | — | |
| Bruce et al43 | 133 | Systemic lupus erythematosus | — | G/A/M | — | |
| Lee et al44 * | 270 | Systemic lupus erythematosus | — | G/A/M | — | |
| Horbach et al45 * | 175 | Systemic lupus erythematosus | — | G/M | G/M | |
| Pengo et al46 | 22 | Antiphospholipid syndrome | — | G | G | |
| Puurunen et al47 | 139 | Antiphospholipid syndrome | — | G | G | |
| Forastiero et al48 * | 233 | Antiphospholipid antibodies | — | G/M | G/M | |
| Swadzba et al49 | 127 | Systemic lupus erythematosus | — | G/M | G/M | |
| Martinuzzo et al50 * | 54 | Pulmonary hypertension | — | G/M | G/M | |
| Atsumi et al51 * | 265 | Autoimmune diseases | — | G/M | G/M | |
| Galli et al52 | 75 | Antiphospholipid antibodies | — | G/M | G/M | |
| Lakos et al53 | 70 | Systemic lupus erythematosus | — | G | G | |
| Nojima et al54 * | 124 | Systemic lupus erythematosus | — | G/M | G/M | |
| Galli et al13 | 59 | Antiphospholipid antibodies | — | G/M | — | |
| Bertolaccini et al55 | 207 | Systemic lupus erythematosus | — | G/M | — | |
| Munoz-Rodriguez et al56 * | 177 | Antiphospholipid syndrome | — | G/M | — | |
. | . | . | . | Isotypes . | . | |
|---|---|---|---|---|---|---|
| Article and reference no. . | No. of patients . | Enrollment criteria . | No. of controls . | Anti—β2-glycoprotein I . | Antiprothrombin . | |
| Cross-sectional | ||||||
| Pasquier et al26 | 241 | Deep vein thrombosis | 157 | G/A/M | G/A/M | |
| Case-control | ||||||
| Vaarala et al27 * | 106 | Myocardial infarction | 106 | G | G | |
| Palosuo et al28 * | 265 | Deep vein thrombosis | 265 | G | G | |
| Previtali et al29 | 79 | Arterial and venous thrombosis | 85 | G/M | G/M | |
| Brey et al30 * | 374/259 | Myocardial infarction/cerebral stroke | 1360 | G | — | |
| Retrospective | ||||||
| Viard et al31 | 47 | Systemic lupus erythematosus | — | G | — | |
| Balestrieri et al32 | 121 | Antiphospholipid syndrome | — | G/M | — | |
| Cabiedes et al33 | 94 | Systemic lupus erythematosus | — | G | — | |
| Cabral et al34 | 15 | Antiphospholipid syndrome | — | G/M | — | |
| Martinuzzo et al35 | 169 | Antiphospholipid antibodies | — | G | — | |
| Amengual et al36 | 120 | Antiphospholipid syndrome | — | G | — | |
| Roubey et al37 | 157 | Systemic lupus erythematosus | — | G | — | |
| Tsutsumi et al38 | 308 | Systemic lupus erythematosus | — | G/M | — | |
| Sanmarco et al39 | 61 | Autoimmune diseases | — | G | — | |
| Day et al40 * | 281 | Antiphospholipid syndrome | — | G/M | — | |
| Fanopoulos et al41 | 48 | Systemic lupus erythematosus | — | G/A/M | — | |
| Zanon et al42 | 227 | Deep vein thrombosis | — | G/M | — | |
| Bruce et al43 | 133 | Systemic lupus erythematosus | — | G/A/M | — | |
| Lee et al44 * | 270 | Systemic lupus erythematosus | — | G/A/M | — | |
| Horbach et al45 * | 175 | Systemic lupus erythematosus | — | G/M | G/M | |
| Pengo et al46 | 22 | Antiphospholipid syndrome | — | G | G | |
| Puurunen et al47 | 139 | Antiphospholipid syndrome | — | G | G | |
| Forastiero et al48 * | 233 | Antiphospholipid antibodies | — | G/M | G/M | |
| Swadzba et al49 | 127 | Systemic lupus erythematosus | — | G/M | G/M | |
| Martinuzzo et al50 * | 54 | Pulmonary hypertension | — | G/M | G/M | |
| Atsumi et al51 * | 265 | Autoimmune diseases | — | G/M | G/M | |
| Galli et al52 | 75 | Antiphospholipid antibodies | — | G/M | G/M | |
| Lakos et al53 | 70 | Systemic lupus erythematosus | — | G | G | |
| Nojima et al54 * | 124 | Systemic lupus erythematosus | — | G/M | G/M | |
| Galli et al13 | 59 | Antiphospholipid antibodies | — | G/M | — | |
| Bertolaccini et al55 | 207 | Systemic lupus erythematosus | — | G/M | — | |
| Munoz-Rodriguez et al56 * | 177 | Antiphospholipid syndrome | — | G/M | — | |
Studies that included multivariate analysis. — indicates not available.